Valuation: XTL Biopharmaceuticals Ltd.

Market Cap 5.45M 1.73B 4.89M 4.5M 4.09M 7.74M 511M 7.95M 53.91M 21.48M 274M 20.44M 20.01M 865M P/E 2024
-7.08x
P/E 2025 -0.96x
Enterprise Value 5.37M 1.7B 4.82M 4.44M 4.03M 7.63M 504M 7.84M 53.16M 21.18M 270M 20.16M 19.73M 853M EV / Sales 2024
47,405,414x
EV / Sales 2025 -
Free-Float
75.44%
Yield 2024 *
-
Yield 2025 -
1 week-7.14%
Current month-7.14%
1 month-18.75%
3 months-40.91%
6 months-35.00%
Current year-45.83%
1 week 1.3
Extreme 1.3
1.5
1 month 1.3
Extreme 1.3
1.6
Current year 1.3
Extreme 1.3
4.4
1 year 1.3
Extreme 1.3
4.4
3 years 1.3
Extreme 1.3
17.1
5 years 1.3
Extreme 1.3
17.1
10 years 1.3
Extreme 1.3
19.2
Manager TitleAgeSince
Chief Executive Officer 56 2025-04-06
Director of Finance/CFO - 2025-11-29
Director TitleAgeSince
Chairman 64 2025-04-06
Director/Board Member 60 2015-02-28
Director/Board Member 59 2020-01-28
Date Insider Type Main position Quantity % Market Cap. Importance
3/18/26 Other

Director

1,000,000 0.1057%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-7.14%-63.89%-60.61% 5.45M
+0.01%+8.40%+58.48%+69.01% 68.22B
+1.22%+10.23%+18.35%+87.67% 59.82B
+0.24%+1.97%+24.62%+94.87% 56.07B
+1.60%+17.36%+32.51%+123.69% 47.67B
-1.32%+6.47%+30.74%+43.37% 45.95B
-3.54%+2.60%+216.44%+864.34% 43.29B
-3.33%+5.73%+23.28%+47.32% 35.66B
-2.19%-3.16%+93.83%+63.14% 34.73B
+2.92%+9.31%-37.01%+410.20% 25.47B
Average -0.47%+4.10%+39.74%+174.30% 42B
Weighted average by Cap. -0.45%+5.40%+52.64%+179.68%

Financials

2024 2025
Net sales 0.45 143.06 0.4 0.37 0.34 0.64 42.29 0.66 4.46 1.78 22.66 1.69 1.66 71.62 -
Net income -1.03M -326M -921K -849K -771K -1.46M -96.29M -1.5M -10.16M -4.05M -51.59M -3.85M -3.77M -163M -6.97M -2.21B -6.25M -5.76M -5.23M -9.9M -653M -10.18M -68.96M -27.48M -350M -26.15M -25.6M -1.11B
Net Debt -1M -319M -901K -831K -754K -1.43M -94.23M -1.47M -9.95M -3.96M -50.48M -3.77M -3.69M -160M -76K -24.11M -68.16K -62.81K -57.04K -108K -7.13M -111K -752K -300K -3.82M -285K -279K -12.07M
Projected Income Statement - Annual - XTL Biopharmaceuticals Ltd.
Logo XTL Biopharmaceuticals Ltd.
X T L Biopharmaceuticals Ltd (Xenograft Technologies Ltd) is an Israel-based biopharmaceutical company engaged in acquisition and development of pharmaceutical drugs for treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
Employees
5
Date Price Change Volume
26-11-10 ILA 1.300 0.00% 0
26-11-09 ILA 1.300 -7.14% 820,000
26-11-06 ILA 1.400 0.00% 374,284
26-11-05 ILA 1.400 0.00% 479,884
26-11-04 ILA 1.400 0.00% 1,748,687
  1. Stock Market
  2. Stocks
  3. XTLB Stock